[LIVN] LivaNova Thesis 2026: Neuromodulation VNS and Cardiopulmonary Specialty Compounder

Key Takeaways

• LivaNova plc (NASDAQ: LIVN), the London-UK-headquartered Neuromodulation-VNS-and-Cardiopulmonary + emerging-multi-cycle-VNS-Depression-Cardiopulmonary-and-Difficult-to-Treat-Depression-Cycle leader, closes FY2025 with selected various aggregate revenue ~$1.15-1.30B (~3-8% YoY-reflecting Neuromodulation-VNS-Epilepsy-and-Cardiopulmonary-Cycle + emerging-multi-cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Readout), adjusted EBITDA ~$215-275M (~19-22% margins), adjusted EPS ~$2.60-3.45, net debt ~$0.40-0.55B (~1.5-2.2x leverage).
• President & CEO Vladimir Makatsaria (since-2024, ~1+ year longtime-LivaNova-CEO + Former-Johnson-Johnson-MedTech-veteran + multi-cycle-MedTech-Cardio-and-Neuromodulation-veteran) leads FY2026 turning on Neuromodulation-VNS-Epilepsy + emerging-multi-cycle-VNS-Difficult-to-Treat-Depression-RECOVER-Pivotal-Trial-2024-Readout + emerging-Cardiopulmonary-Heart-Lung-Machine + emerging-Adjacent-Heart-Failure-and-Hypertension + emerging-International-Expansion + Vladimir-Makatsaria-CEO-strategic-execution.
• Sector context: Health-Care + Neuromodulation-VNS-and-Cardiopulmonary + emerging-multi-cycle-VNS-Difficult-to-Treat-Depression-Cycle + emerging-Cardiopulmonary-Heart-Lung-Machine-Demand.

Company Background

LivaNova plc (NASDAQ: LIVN), headquartered in London-UK, is a Neuromodulation-VNS-and-Cardiopulmonary + emerging-multi-cycle-VNS-Depression-Cardiopulmonary-and-Difficult-to-Treat-Depression-Cycle leader providing distinctive multi-cycle Neuromodulation-VNS-Epilepsy + emerging-VNS-Difficult-to-Treat-Depression + emerging-Cardiopulmonary-Heart-Lung-Machine + emerging-Adjacent-Heart-Failure-and-Hypertension services to substantial multi-cycle Epilepsy-Neurology-VNS-Implant-Patient + multi-cycle-emerging-Difficult-to-Treat-Depression-VNS-Patient + multi-cycle-emerging-Cardiopulmonary-Hospital-Cardiac-Surgery-Customer + multi-cycle-emerging-Heart-Failure-and-Hypertension-Patient + multi-cycle-emerging-International-Europe-and-Asia-Pacific-Hospital customer base.

The company has distinctive multi-cycle LivaNova-and-London-UK-and-Neuromodulation-and-Cardiopulmonary heritage: founded 2015 as LivaNova-via-Sorin-and-Cyberonics-merger ($2.7B+ combined enterprise providing Neuromodulation-VNS-and-Cardiopulmonary-Scale + 1979-Cyberonics-Houston-TX-historical-VNS-Founder-Reese-Terry + 1956-Sorin-Italy-historical-Cardiopulmonary-Founder); 2015 substantial NASDAQ LivaNova-Merger-IPO; 2018 substantial CardiacRhythm-Management-CRM-Divestment (~$200M divest to MicroPort providing focus-on-Neuromodulation-VNS-and-Cardiopulmonary); 2020 substantial Heart-Failure-and-Hypertension-Pipeline-Acquisition; 2021-2024 substantial Multi-Cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Investment; 2024 substantial CEO-Succession-Vladimir-Makatsaria-from-Damien-McDonald-Former-CEO + Multi-Cycle-VNS-Difficult-to-Treat-Depression-Strategy-Acceleration; multi-cycle-disciplined-Neuromodulation-VNS-and-Cardiopulmonary-Pipeline-Investment; Vladimir-Makatsaria-CEO-since-2024 + Multi-Cycle-MedTech-Cardio-and-Neuromodulation-Strategy.

FY2025 closes with selected various aggregate revenue ~$1.15-1.30B (~3-8% YoY-reflecting Neuromodulation-VNS-Epilepsy-and-Cardiopulmonary-Cycle + emerging-multi-cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Readout-Anticipation + emerging-International-Expansion), adjusted EBITDA ~$215-275M (~19-22% margins), adjusted EPS ~$2.60-3.45 (steady-Neuromodulation-VNS-and-Cardiopulmonary-margin-execution), net debt ~$0.40-0.55B (~1.5-2.2x leverage), and ~53-55M shares outstanding under President & CEO Vladimir Makatsaria (since-2024).

Deep-Dive 1 — Neuromodulation-VNS-Epilepsy-and-Cardiopulmonary-Heart-Lung-Machine

The Neuromodulation-VNS-and-Cardiopulmonary franchise deep-dive covers distinctive multi-cycle ~3,000-3,200 employees + ~London-UK-HQ + ~Houston-TX-VNS-Cyberonics-historical-and-Mirandola-Italy-Cardiopulmonary-Sorin-historical-Globally-Positioned-Neuromodulation-and-Cardiopulmonary-Manufacturing-Facility across UK-and-US-and-Italy-and-Europe-and-Asia-Pacific. Revenue mix: Neuromodulation-VNS ~37-42% revenue (Epilepsy-VNS-Implant-Demipulse-and-Aspire-and-SenTiva + emerging-multi-cycle-Difficult-to-Treat-Depression-VNS-Pivotal-RECOVER-Trial-2024-Readout + emerging-Heart-Failure-and-Hypertension) + Cardiopulmonary ~55-61% revenue (Heart-Lung-Machine-S5-and-S3-and-Connect-and-Stockert + Oxygenator-Adult-and-Pediatric + Cannulae-and-Tubing + Autotransfusion-Cell-Salvage + emerging-Cardiac-Surgery-Modernization) + Advanced-Circulatory-Support-ACS-and-Adjacency ~2-7% revenue (legacy + emerging-Heart-Failure-Acute-Cardiac-Support).

Substantial multi-cycle Epilepsy-Neurology-VNS-Implant-Patient (~500,000+ Drug-Resistant-Epilepsy-Patient-Population-US) + multi-cycle-emerging-Difficult-to-Treat-Depression-VNS-Patient (~5M+ Difficult-to-Treat-Depression-Patient-Population-US) + multi-cycle-emerging-Cardiopulmonary-Hospital-Cardiac-Surgery-Customer + multi-cycle-emerging-Heart-Failure-and-Hypertension-Patient + multi-cycle-emerging-International-Europe-and-Asia-Pacific-Hospital. 2015-NASDAQ-LivaNova-Sorin-Cyberonics-Merger-IPO + 2018-CardiacRhythm-Management-CRM-Divestment + 2020-Heart-Failure-and-Hypertension-Pipeline-Acquisition + 2021-2024-Multi-Cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Investment + 2024-CEO-Succession-Vladimir-Makatsaria transformational-platform, emerging-multi-cycle Neuromodulation-VNS-Epilepsy-Demand + emerging-VNS-Difficult-to-Treat-Depression-CMS-NCD-Coverage-and-Pivotal-RECOVER-Trial-2024-Readout-Anticipation + emerging-Cardiopulmonary-Heart-Lung-Machine-Demand-Cardiac-Surgery-Volume-Recovery + emerging-Heart-Failure-and-Hypertension-Adjacency + emerging-International-Europe-and-Asia-Pacific-Hospital-Demand structural-tailwinds. Competing in Neuromodulation-VNS space with Medtronic (MDT DBS-Deep-Brain-Stimulation), Boston Scientific (BSX DBS-and-Pain-Stimulation), Abbott (ABT DBS-and-Spinal-Cord-Stimulation), Nevro (NVRO Spinal-Cord-Stimulation), inspire-Medical-Systems (INSP Obstructive-Sleep-Apnea-Hypoglossal-Nerve-Stimulation), Axonics (AXNX Sacral-Nerve-Stimulation-acquired-Boston-Scientific-2024); Cardiopulmonary-Heart-Lung-Machine space with Maquet/Getinge (Swedish-Cardiopulmonary), Terumo (Japanese-Cardiopulmonary), Medtronic-Cardiopulmonary, Edwards Lifesciences (EW Cardiac-Surgery-Adjacent); and private-equity-Carlyle-Apollo-KKR-Blackstone-Bain-CD&R-EQT-Permira-CVC-Bridgepoint-Cinven-Ardian-TPG-Veritas-Genstar-Hellman-Friedman.

Deep-Dive 2 — Vladimir-Makatsaria-CEO-and-2024-CEO-Succession-and-VNS-Difficult-to-Treat-Depression-Capital-Allocation

The Vladimir-Makatsaria + 2024-CEO-succession + multi-decade compounder thesis + 2015-Sorin-Cyberonics-Merger-and-2024-RECOVER-Pivotal-Trial-Readout deep-dive covers Vladimir-Makatsaria-CEO (since-2024, 1+ year longtime-LivaNova-CEO + Former-Johnson-Johnson-MedTech-veteran + multi-cycle-MedTech-Cardio-and-Neuromodulation-veteran) expertise + Damien-McDonald-Former-CEO-leadership-succession-2024 + multi-cycle-Sorin-Cyberonics-Heritage-Merger-Capital-Management leadership-continuity, 1956-Sorin-Italy-historical-Cardiopulmonary-Founder + 1979-Cyberonics-Houston-TX-historical-VNS-Founder-Reese-Terry + 2015-substantial-Sorin-Cyberonics-merger-LivaNova-NASDAQ-IPO ($2.7B+ combined enterprise providing Neuromodulation-VNS-and-Cardiopulmonary-Scale) + 2018-substantial-CardiacRhythm-Management-CRM-Divestment ($200M divest to MicroPort providing focus-on-Neuromodulation-VNS-and-Cardiopulmonary) + 2020-substantial-Heart-Failure-and-Hypertension-Pipeline-Acquisition + 2021-2024-substantial-Multi-Cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Investment + 2024-substantial-CEO-Succession-Vladimir-Makatsaria + Multi-Cycle-VNS-Difficult-to-Treat-Depression-Strategy-Acceleration transformational-platform, multi-cycle-disciplined-Neuromodulation-VNS-and-Cardiopulmonary-Pipeline-Investment discipline, and no-dividend (Cash-Flow-Reinvested-in-Neuromodulation-VNS-and-Cardiopulmonary-R&D-and-Pipeline) + multi-cycle-emerging-share-buyback-only (~$25-100M/yr discretionary).

Track IG-equivalent balance sheet (Baa3/BBB- ~1.5-2.2x leverage Neuromodulation-VNS-and-Cardiopulmonary-and-Pipeline-Investment + multi-cycle-emerging-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Readout-debt-paydown), multi-cycle-LivaNova-Capital-Management leadership-continuity, and emerging-strategic-acquisition-target optionality (Neuromodulation-VNS-and-Cardiopulmonary-M&A-Activity Medtronic, Boston Scientific, Abbott, Johnson Johnson MedTech, Maquet/Getinge, Terumo, Edwards Lifesciences).

Capital Position + Balance Sheet

Capital position is IG-equivalent (Baa3/BBB- 1.5-2.2x leverage Neuromodulation-VNS-and-Cardiopulmonary-and-Pipeline-Investment + multi-cycle-emerging-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Readout-debt-paydown). Capital allocation reflects no-dividend (Cash-Flow-Reinvested-in-Neuromodulation-VNS-and-Cardiopulmonary-R&D-and-Pipeline), multi-cycle-emerging-share-buyback-only ($25-100M/yr discretionary), multi-cycle-disciplined-Neuromodulation-VNS-and-Cardiopulmonary-Pipeline-Investment ($50-200M/yr R&D-and-Bolt-on-M&A), and multi-cycle-CapEx-Neuromodulation-VNS-and-Cardiopulmonary-Manufacturing-Facility (~$45-75M/yr).

Net-debt position ~$0.40-0.55B provides multi-cycle-emerging-Neuromodulation-VNS-and-Cardiopulmonary-Bolt-on-M&A-and-Pipeline-Investment-capacity. 2021-2024-Multi-Cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-Investment ($200-400M cumulative deployment) provides emerging-multi-cycle-VNS-Difficult-to-Treat-Depression-Pivotal-RECOVER-Trial-2024-Readout-and-Difficult-to-Treat-Depression-Commercial-Launch-revenue-and-margin-accretion.

Key Core Metrics

• Revenue: ~$1.15-1.30B (~3-8% YoY-reflecting Neuromodulation-VNS-Epilepsy-and-Cardiopulmonary-Cycle)
• Adjusted EBITDA: ~$215-275M (~19-22% margins)
• Adjusted EPS: ~$2.60-3.45
• Net debt: ~$0.40-0.55B (~1.5-2.2x leverage)
• Shares outstanding: ~53-55M
• Dividend: None (Cash-Flow-Reinvested-in-Neuromodulation-VNS-and-Cardiopulmonary-R&D-and-Pipeline)
• Revenue mix: Neuromodulation-VNS ~37-42% + Cardiopulmonary ~55-61% + ACS-and-Adjacency ~2-7%
• Geographic: UK-and-US-and-Italy-and-Europe-and-Asia-Pacific

Market Evaluation

At ~$45-65 per share, equity value ~$2.40-3.55B, EV ~$2.80-4.10B, providing ~17-25x EPS and ~10-15x EV/EBITDA. The market evaluation reflects emerging-multi-cycle Neuromodulation-VNS-Epilepsy-Demand + emerging-VNS-Difficult-to-Treat-Depression-CMS-NCD-Coverage-and-Pivotal-RECOVER-Trial-2024-Readout-Anticipation (~5M+ Difficult-to-Treat-Depression-Patient-Population-US Total-Addressable-Market) + emerging-Cardiopulmonary-Heart-Lung-Machine-Demand-Cardiac-Surgery-Volume-Recovery + emerging-Heart-Failure-and-Hypertension-Adjacency + emerging-International-Europe-and-Asia-Pacific-Hospital-Demand structural-tailwinds against Neuromodulation-VNS-Competitive-Pressure (Medtronic-DBS-and-Spinal-Cord-Stimulation + Boston-Scientific-DBS + Abbott-DBS-and-Spinal-Cord-Stimulation + Nevro-Spinal-Cord-Stimulation + inspire-Medical-Systems-Hypoglossal-Nerve-Stimulation) + emerging-Cardiopulmonary-Heart-Lung-Machine-Maquet-Getinge-Terumo-Competition + emerging-VNS-Difficult-to-Treat-Depression-RECOVER-Trial-Readout-Binary-Risk + emerging-CMS-NCD-Coverage-Reimbursement-Variability structural-headwinds. Vladimir-Makatsaria-CEO + multi-cycle-disciplined-Neuromodulation-VNS-and-Cardiopulmonary-Pipeline-Investment execution remains primary FY2026 multi-cycle-emerging value-creation lever.